Trial · NCT07905456
Efficacy of Thymus Vulgaris Mouthwash in the Management of Biofilm-Induced Gingivitis
NCT07905456, Phase 2, Not yet recruiting, University of Sulaimani
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Thymus Vulgaris Mouthwash in the Management of Biofilm-Induced Gingivitis. Trials, record NCT07905456. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905456
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Thymus Vulgaris Mouthwash in the Management of Biofilm-Induced Gingivitis
- NCT number
- NCT07905456
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- University of Sulaimani
- Conditions
- Plaque-Induced Gingivitis
- Interventions
- 0.2% Thymus vulgaris mouthwash, Chlorhexidine 0,12%, Placebo mouthwash
- First posted
- 2026-10-29
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Bleeding on Probing (BoP) | Baseline, 14 days, and 30 days | Bleeding on Probing (BOP) will be assessed by gently inserting a periodontal probe into the gingival sulcus or periodontal pocket, parallel to the long axis of the tooth, using a probing force of approximately 20-25 grams. Bleeding will be assessed 15-30 seconds after probing at each site. Each site will be scored as 0 (no bleeding) or 1 (bleeding present). The possible score for each site ranges from 0 to 1, with higher scores indicating the presence of bleeding and a worse outcome. If expressed as a percentage, BOP will be calculated as the number of sites exhibiting bleeding divided by the total number of sites examined, multiplied by 100; percentages range from 0% to 100%, with higher values indicating more bleeding and a worse outcome. |
| Secondary | Plaque Index (PI) | Baseline, 14 days, and 30 days | The Modified Quigley-Hein Plaque Index (MQHI) will be used to assess the amount of accumulated dental plaque on all tooth surfaces, excluding the third molars. Six surfaces per tooth will be examined: mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual. Dental plaque will be visualized using a disclosing agent (GC Tri Plaque ID Gel, GC Corporation, Japan). Each examined surface will be scored on a scale from 0 to 5 according to the Modified Quigley-Hein Plaque Index criteria, with 0 indicating no plaque and 5 indicating extensive plaque accumulation. The participant's plaque score will be calculated as the mean score of all examined surfaces. Possible mean scores range from 0 to 5, with higher scores indicating greater plaque accumulation and a worse outcome. |
| Secondary | Gingival Index (GI) | Basline, 14 days, and 30 days. | Gingival Index (GI) will be used to assess the severity of gingival inflammation on the mesial, distal, buccal, and lingual surfaces of all teeth, excluding the third molars. The gingiva will be examined under adequate illumination, and a UNC-15 periodontal probe will be used gently to assess gingival tissue consistency and bleeding tendency where indicated by the index criteria. Each surface will be assigned a score from 0 to 3: 0 indicates normal gingiva with no inflammation; 1 indicates mild inflammation with slight changes in color and texture but no bleeding on probing; 2 indicates moderate inflammation with redness, edema, and bleeding on probing; and 3 indicates severe inflammation with marked redness and edema, ulceration, and a tendency toward spontaneous bleeding. The participant's GI score will be calculated as the mean score of all examined surfaces. Possible mean scores range from 0 to 3, with higher scores indicating more severe gingival inflammation and a worse outcome. |
| Secondary | Salivary Interleukin-1 Beta (IL-1β) Concentration | Baseline, 14 days, and 30 days. | Salivary interleukin-1 beta (IL-1β) concentration will be quantified using an enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's instructions for sample preparation, assay procedures, and result calculation. Results will be expressed in picograms per milliliter (pg/mL). |
| Secondary | Salivary Matrix Metalloproteinase-8 (MMP-8) Concentration | Baseline, 14 days, and 30 days. | Salivary matrix metalloproteinase-8 (MMP-8) concentration will be quantified using an enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's instructions for sample preparation, assay procedures, and result calculation. Results will be expressed in picograms per milliliter (pg/mL). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905456
GET https://conductscience.org/api/trials/v1/NCT07905456/registered